ABSTRACT
Oral cavity care is very much associated with perceptions of pain and anxiety. Oral health practitioners have many solutions in order to reduce patients' apprehension, and an alternative non-drug technique has increased: the use of virtual reality (VR). The aim of this review is to highlight the contribution of virtual reality headsets in reducing anxiety and pre- and post- operative pain in patients having oral surgery. PubMed and Cochrane Library have been searched for scientific articles with MESH words «virtual reality ¼, « oral surgery ¼, « anxiety ¼ and « pain ¼. 8 articles were identified and 6 met the inclusion criteria. Among the 6 articles analyzed, 4 were control trials and 2 were methodological descriptions. 2 clinical trials found statistically significant results on the outcome measures of pre-operative and post-operative anxiety and pain felt. The use of VR in oral surgery seems to have an impact in reducing anxiety and pre- and post- operative pain, but more studies are needed to confirm its effectiveness.
Subject(s)
Oral Surgical Procedures , Surgery, Oral , Virtual Reality , Anxiety/etiology , Anxiety/prevention & control , Humans , Pain, Postoperative/diagnosis , Pain, Postoperative/etiology , Pain, Postoperative/prevention & controlABSTRACT
Antiresorptives and antiangiogenics are treatments that have proven effective in oncology and the treatment of osteoporosis and they are increasingly prescribed. The care of these patients requires collaboration between the prescriber and the oral health professional to establish an optimized treatment plan. Therapeutic education of the patient is essential for him to understand the issues of good oral health and the adverse effects that can be caused by these treatments. The management is essentially based on the individual benefit/risk balance resulting from the general, local and inherent of the molecule risk factors. Management of drug-related osteonecrosis of the jaw should be as early as possible.
Subject(s)
Angiogenesis Inhibitors/adverse effects , Bone Density Conservation Agents/adverse effects , Diphosphonates/adverse effects , Jaw Diseases/chemically induced , Osteonecrosis/chemically induced , Bisphosphonate-Associated Osteonecrosis of the Jaw/etiology , Bisphosphonate-Associated Osteonecrosis of the Jaw/pathology , Bisphosphonate-Associated Osteonecrosis of the Jaw/prevention & control , Bisphosphonate-Associated Osteonecrosis of the Jaw/surgery , Bone Density Conservation Agents/therapeutic use , Bone Resorption/drug therapy , Dental Care/methods , Diphosphonates/history , Diphosphonates/therapeutic use , History, 19th Century , History, 20th Century , Humans , Jaw Diseases/diagnostic imaging , Jaw Diseases/history , Jaw Diseases/prevention & control , Neoplasms/drug therapy , Occupational Diseases/history , Oral Surgical Procedures/adverse effects , Oral Surgical Procedures/methods , Osteonecrosis/diagnostic imaging , Osteonecrosis/prevention & control , Osteoporosis/drug therapy , Phosphorus/toxicity , Postoperative Complications/chemically induced , Tooth Extraction/adverse effectsABSTRACT
BACKGROUND: The purpose of pharmacovigilance (drug safety) is collection, detection, assessment, monitoring, and prevention of adverse effects with pharmaceutical products. It is meant to identify, characterize, prevent, or minimize actual or potential risks relating to medicinal products. To prevent these adverse effects and improve our practice, health professionals have a duty to report side effects to assess this risk and evaluate the benefit/risk requirements. Mitotane (Lysodren) is used for treating adrenocortical carcinoma. Currently, no side effects concerning oral and genital mucosa have been reported. CASE SUMMARY: This case report is about a 50 years old woman. Six months after the initiation on mitotane treatment, she developed erosive lesions located on the oral and vaginal mucosa. These drug reactions were diagnosed as erosive lichen planus by the biopsy. This lichenoid lesions were resistant to the usual treatments, mitotane being at the time not replaceable. CONCLUSION: This case describes an unreported adverse effect of mitotane, it is - to our knowledge - the 1st description of erosive lichenoid drug reaction due to Mitotane.
